Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2018

View Archived Issues

Local factors greatly affect myelination state

Pharmacokinetic data of anti-CD22 TTC BAY-1862864 suggest good stability and biodistribution

[225Ac]FPI-1434 demonstrates theranostic potential in multiple preclinical models of human cancer

Strong tumor-targeting in mice treated with the [99mTc]-labeled CCK2R-antagonist DGA1

Hisamitsu begins phase II trial in Japan with HP-5070 for primary local hyperhidrosis

ConsortiaTx signs license for foundational intellectual property related to CTX-944

Chromosome microarray reveals a chromosome 17q duplication and deletion in a patient

Weill Cornell Medicine describes improved CXCR4 ligands for PET imaging

Chengdu Euthare Therapeutics identifies CDK4 and CDK6 inhibitors

Raf kinase regulates mast cell activation, allergic response

Ocean University of China patents new antivirals

Japanese researchers present ROR-gammaT antagonists

CureVac begins phase I trial with prophylactic mRNA rabies vaccine CV-7202

Bayer synthesizes new CDK9 inhibitors

FDA approves Afluria Quadrivalent for use in individuals age 6 months and older

Plinabulin + Neulasta reduce grade 3/4 CIN and bone pain in phase II trial

Probiodrug discovers QPCT inhibitors

ADCT-602 studied in phase I/II trial for recurrent or refractory B-cell ALL

Darolutamide significantly extends metastasis-free survival in nonmetastatic CRPC

Celgene reports PFS improvement with Revlimid in smoldering multiple myeloma

Zymeworks and Leo Pharma enter licensing and research collaboration for bispecific antibodies

FDA agrees with Scynexis on phase III plans for ibrexafungerp in VVC

Enanta begins phase IIa study of EDP-938 to treat RSV infection

First positive phase III data for PIK3CA inhibitor alpelisib in breast cancer

Xortx's pre-IND meeting with FDA identifies accelerated clinical development plan for XRx-008

Santhera begins phase Ib/IIa study of POL-6014 in cystic fibrosis

Phase I study indicates lower effective dose with [18F]PSMA-11 than other PSMA ligands

Biogen discontinues development of vixotrigine for painful lumbosacral radiculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...